Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma
NCT02662504 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6
Last updated 2026-02-05
Summary
Malignant pleural mesothelioma (MPM) is an aggressive tumour with poor prognosis (median survival \<13 months), and high resistance to chemotherapy. Extended pleurectomy/decortication (eP/D) is a debulking surgery of MPM but cannot be considered as a curative treatment. Therefore it has been suggested that eP/D may be of interest if combined with intra-operative treatment and adjuvant therapies.
Photodynamic Therapy (PDT) is an innovative treatment based on the rationale that tumour cells, if previously treated with photosensitizing drugs (Photofrin), will die when exposed to light at a particular wavelength. Interestingly PDT might also stimulate anti-tumour immune response through the release of tumour antigens and induced inflammation.
PDT was tested in phase I-II trials for MPM in combination with EPP or eP/D, and chemotherapy. US studies from J Friedberg et al found very promising survival results in MPM when combining eP/D, but not EPP, intra-operative PDT and chemotherapy (cisplatin-pemetrexed), with a median overall survival of 31.7 months.
However, the definitive value of intra-pleural PDT combined to eP/D in the treatment of MPM still need to be validated. The same multimodal treatment has been established in Lille, the French national expert centre for MPM, with the help of our american colleagues. Therefore, this phase II trial proposes to patients to benefit from the combination of eP/D, intra-operative PDT then chemotherapy by cisplatin-pemetrexed and prophylactic radiotherapy.
Primary endpoint is the feasibility for the patients to have the full multimodal treatment of MPM including intrapleural PDT without unacceptable or unexpected grade III-IV toxicities. Secondary endpoints are PFS, OS, ORR, and quality of life. If the feasibility of such treatment would be confirmed in France, a multicentric, randomized trial comparing this experimental treatment vs control arm (same multimodal treatment without PDT) is planned.
Conditions
- Malignant Pleural Mesothelioma
Interventions
- DEVICE
-
photodynamic therapy (PDT)
Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks. After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the "pleural" cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period.
- PROCEDURE
-
thoracic surgery Pleurectomy / extended Decortication
extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
- DRUG
-
Adjuvant chemotherapy
Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
Sponsors & Collaborators
-
Institut National de la Santé Et de la Recherche Médicale, France
collaborator OTHER_GOV - collaborator OTHER
-
Région Nord-Pas de Calais, France
collaborator OTHER -
University Hospital, Lille
lead OTHER
Principal Investigators
-
Arnaud Scherpereel, MD, PhD · University Hospital, Lille
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-16
- Primary Completion
- 2018-03-12
- Completion
- 2018-03-13
Countries
- France
Study Locations
More Related Trials
-
Trimodality Therapy for Malignant Pleural Mesothelioma
NCT01343264 ·Status: UNKNOWN
-
Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)
NCT01134146 ·Status: COMPLETED ·Phase: PHASE1
-
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma
NCT03269227 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Short Neoadjuvant Hemithoracic IMRT for MPM
NCT00797719 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The IMmunotherapy Pleural 5-ALA PDT
NCT04400539 ·Status: RECRUITING ·Phase: PHASE2
-
Stereotactic Body Radiotherapy Followed by Surgical Stabilization for Patients With Unstable Spinal Metastases
NCT02622841 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
NCT05655078 ·Status: RECRUITING ·Phase: NA
-
SBRT + TACE for Primary Hepatocellular Carcinoma
NCT00746655 ·Status: WITHDRAWN ·Phase: NA
-
Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
NCT02780648 ·Status: COMPLETED ·Phase: NA
-
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax
NCT05524064 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
NCT06306638 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Rapid Radiation Therapy for Painful Osseous Metastatic Disease
NCT01391234 ·Status: COMPLETED ·Phase: NA
-
Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases
NCT02159742 ·Status: ACTIVE_NOT_RECRUITING
-
Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
NCT02634710 ·Status: COMPLETED ·Phase: NA
-
Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow
NCT02145286 ·Status: UNKNOWN ·Phase: NA
-
Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis
NCT01757717 ·Status: COMPLETED ·Phase: NA
-
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
NCT03704662 ·Status: RECRUITING ·Phase: NA
-
A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain
NCT00802659 ·Status: TERMINATED ·Phase: NA
-
Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy
NCT07289646 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Functional Imaging of Treatment Effects: A Companion Protocol to a Study of Extracranial Stereotactic Radioablation in Early Stage Non-Small Cell Lung Cancer
NCT00246116 ·Status: COMPLETED ·Phase: NA
-
Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction
NCT03564054 ·Status: TERMINATED ·Phase: NA
-
The Use of Photobiomodulation in the Management of Radiodermatitis in Patients in Palliative Care. A Prospective Study.
NCT05561803 ·Status: WITHDRAWN
-
Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer
NCT02206724 ·Status: WITHDRAWN ·Phase: NA
-
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
NCT02608385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Stereotactic Body Radiotherapy Followed by Surgical Stabilization in Spinal Metastases
NCT05060653 ·Status: WITHDRAWN ·Phase: NA